-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On October 17, FiercePharma released the list of the top 10 vaccine companies in the world
.
Several joys and some sorrows, the outbreak of the new crown not only stabilized Pfizer's top position and added several new upstarts, but also shook the long-term backbone of GSK, Sanofi, Merck and other companies in the field of vaccines
.
Since the pandemic, Comirnaty, the new crown vaccine from Pfizer/BioNTech, has been at the top
of the list.
Before the new crown, Pfizer's vaccine business was dominated by the pneumonia vaccine Prevnar 13, which had sales of $5.
85 billion in 2019, accounting for 89% of the total revenue of the vaccine business; Although the Prevnar line of products also sold $5.
27 billion in 2021, it was far less than the $36.
8 billion in revenue
brought by Comirnaty.
Pfizer's other vaccines, such as the meningitis B vaccine Trumenba, also generated $118 million in revenue
in 2021.
In August this year, Pfizer announced positive clinical data for respiratory syncytial virus (RSV) vaccine phase III, which will compete with
strong competitors such as GSK and Johnson & Johnson.
Analysts predict Pfizer's RSV vaccine will contribute $2.
1 billion in revenue
by the end of 2030.
It is worth noting that there are 2 Chinese companies in the list, China Sinovac and Zhifei Biotechnology
.
Thanks to the huge revenue brought by the new crown vaccine, Sinovac's sales increased nearly 3 times in 2021, surpassing Moderna and ranking among the top three, with the new crown vaccine CoronaVac being the main driving force
.
In addition, Sinovac also has vaccines
against seasonal and pandemic influenza, polio, hepatitis A, hepatitis B, pneumococcus and so on.
Zhifei Biologics is best known as the Chinese agent
of Merck's HPV vaccine Gardasil/Gardasil 9.
At present, HPV vaccine is already the cornerstone of Zhifei Biotech's business, and before the agreement with Merck in 2018, Zhifei Biotech's revenue was about 700 million yuan, and in 2020, it soared to 15.
2 billion yuan
.
Gardasil 9, which is represented by Zhifei Biologics, has administered nearly 10.
2 million doses in China, and in 2022H1 it has nearly quadrupled to about 9.
3 million doses
.
In August this year, the China Food and Drug Administration approved the expansion of Gardasil 9 to women aged 9~45, which is expected to be further released
.
In addition to HPV, Zhifei Biotech has also cooperated with Merck on a number of vaccines, including rotavirus vaccine RotaTeq, pneumococcal polysaccharide vaccine Pneumovax 23 and hepatitis A vaccine Vaqta
.
Moderna's new crown vaccine Spikevax and Pfizer/BioNTech new crown vaccine Comirnaty have always been in a competitive relationship, you chase me
.
In August 2022, Moderna also sued Pfizer/BioNTech for COVID vaccine infringement, arguing that the latter "plagiarized" its breakthrough technology
.
In addition, Moderna's product pipeline includes vaccines
against influenza, RSV, HIV, shingles, Zika, Nipah and more.
Merck's vaccine revenue core product is the HPV vaccine Gardasil/Gardasil 9, which reported sales of $5.
7 billion in 2021, up from $3.
9 billion during the pandemic in 2020
.
Thanks to strong growth in the Chinese market, Gardasil/Gardasil 9 continued to thrive in 2022H1, achieving $3.
1 billion in revenue
.
Merck also has a range of blockbuster vaccines, including ProQuad to prevent measles, mumps, rubella and chickenpox, and Varivax for chickenpox only, which generated a total of $2.
1 billion in revenue
in 2021.
The company's RotaTeq vaccine for the prevention of rotavirus in young children continues to climb steadily, reaching $807 million
in 2021.
GSK vaccines include shingles, meningitis, influenza, hepatitis, etc
.
The shingles vaccine Shingrix, the most important product in GSK's vaccine segment, more than doubled sales to £1,429 million in 2022H1, driven by a
recovery in demand in Europe and the US and strong commercial execution to put shingles vaccination ahead of time.
Although Sanofi does not have the blessing of the new crown vaccine, it has been a world leader in flu vaccines, and still brought in about $3.
1 billion in sales
in 2021.
Sanofi also has several other products, including polio, pertussis, Haemophilus influenzae type b and meningitis vaccines
.
Although AstraZeneca's Vaxzevria is also one of the first new crown vaccines to be recognized by regulators, it is very difficult
to develop the market due to factors such as reduced effectiveness, delivery delays, and thrombosis safety issues.
At the end of February 2021, Johnson & Johnson's new crown vaccine was also approved by the FDA, and although the momentum has also declined due to problems such as efficacy and thrombosis safety, it brought in about $1 billion in revenue in the
first half of this year.
Resources
Resources
The top 10 vaccine companies worldwide（fiercepharma.
com）
com）
